+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease



Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease



Journal of Pediatrics 163(2): 521-526



To determine the most effective first-line rescue therapy for intravenous immunoglobulin (IVIG) nonresponders, using IVIG, prednisolone, or both, to prevent coronary artery abnormalities (CAAs). We retrospectively reviewed the clinical records of 359 consecutive patients with Kawasaki disease who failed to respond to initial IVIG. CAAs up to 1 month after treatment were less common in the IVIG+prednisolone group (15.9%) than in the IVIG group (28.7%, P = .005) and the prednisolone group (30.6%, P = .01). The IVIG+prednisolone group had significantly lower risks of failing to respond to first-line rescue therapy (aOR 0.16, 95% CI 0.09-0.31), CAAs up to 1 month (aOR 0.46, 95% CI 0.27-0.90), and CAAs at 1 month (aOR 0.40, 95% CI 0.18-0.91) than the IVIG group. In the prednisolone and IVIG+prednisolone groups, risk score, day of illness at first-line rescue therapy, prednisolone monotherapy, and resistance to first-line rescue therapy were independent risk factors for CAA. Sex and resistance to first-line rescue therapy were independent risk factors in the IVIG group. IVIG+prednisolone may be superior to IVIG or prednisolone as first-line rescue therapy in the treatment of IVIG nonresponders. To establish the efficacy of rescue therapy with IVIG+prednisolone following nonresponse to initial IVIG, a prospective randomized trial is warranted.

(PDF emailed within 0-6 h: $19.90)

Accession: 052902332

Download citation: RISBibTeXText

PMID: 23485027

DOI: 10.1016/j.jpeds.2013.01.022


Related references

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?. Korean Circulation Journal 47(2): 179-181, 2017

Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial. Bmc Pediatrics 18(1): 200, 2018

Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease. International Archives of Allergy and Immunology 164(2): 83-88, 2014

Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials. Zhonghua Yi Xue Za Zhi 91(18): 1259-1264, 2012

Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease. Yonsei Medical Journal 55(5): 1260-1266, 2015

Prednisolone added to intravenous immunoglobulin treatment improves outcome in children with severe Kawasaki disease. Archives of Disease in Childhood. Education and Practice Edition 98(2): 77-78, 2013

Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Lancet. Child and Adolescent Health 2(12): 855-862, 2018

Recurrent Kawasaki disease resistant to initial treatment with intravenous immunoglobulin. Sudanese Journal of Paediatrics 12(2): 65-69, 2012

A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease. Italian Journal of Pediatrics 44(1): 33, 2018

Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy. Nihon Rinsho. Japanese Journal of Clinical Medicine 72(9): 1641-1649, 2015

Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey. Pediatrics International 49(4): 427-430, 2007

Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. European Journal of Pediatrics 163(4-5): 229-233, 2004

Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatric Infectious Disease Journal 30(10): 871-876, 2012

Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease. Journal of Korean Medical Science 23(4): 718-722, 2008

Recurrence of Fever After Initial Intravenous Immunoglobulin Treatment in Children With Kawasaki Disease. Clinical Pediatrics 57(2): 189-192, 2017